The Effect of Sacubitril/Valsartan in a Dialysis Patient with Severe Heart Failure*  

作　　者：Pingping Kong Yanna Dou Xiaoyang Wang Jing Xiao Zhanzheng Zhao Pingping Kong;Yanna Dou;Xiaoyang Wang;Jing Xiao;Zhanzheng Zhao(The Nephrology Centre Department of the First Affiliated Hospital of Zhengzhou, Zhengzhou, China;Nephrology Institute of Zhengzhou University, Zhengzhou, China)

机构地区：[1]The Nephrology Centre Department of the First Affiliated Hospital of Zhengzhou, Zhengzhou, China [2]Nephrology Institute of Zhengzhou University, Zhengzhou, China

出　　处：《Case Reports in Clinical Medicine》2021年第7期197-202,共6页临床医学病理报告（英文）

摘　　要：Heart failure (HF) is a major comorbidity in patients with end-stage renal disease (ESRD). The pathogenesis of HF in patients on renal replacement therapy represents the confluence of several traditional and nontraditional vascular risk factors, unique to the milieu of chronic kidney disease and the dialysis modality<a href="#ref1"> [1]</a>. The purpose of this report is to describe the efficacy and safety of sacubitril/valsartan for an ESRD patient on hemodialysis therapy conmbined with heart failure with reduced ejection fraction (HFrEF). A 35-year-old woman was undergoing hemodialysis due to ESRD and suffering from heart failure with reduced ejection fraction. Because of worsening heart failure and hypertension, she was prescribed with sacubitril/valsartan at a dose of 50 mg twice a day, spironolactone at a dose of 20 mg three times a day and metoprolol at a dose of 23.75 mg once daily. There was a symptomatic improvement with the heart failure and reduction in NT-proBNP level, accompanied by a decrease of blood pressure after using sacubitric/valsartan. In conclusion, it is safe and effective to take sacubitril/valsartan in this hemodialysis patient with severe heart failure.Heart failure (HF) is a major comorbidity in patients with end-stage renal disease (ESRD). The pathogenesis of HF in patients on renal replacement therapy represents the confluence of several traditional and nontraditional vascular risk factors, unique to the milieu of chronic kidney disease and the dialysis modality<a href="#ref1"> [1]</a>. The purpose of this report is to describe the efficacy and safety of sacubitril/valsartan for an ESRD patient on hemodialysis therapy conmbined with heart failure with reduced ejection fraction (HFrEF). A 35-year-old woman was undergoing hemodialysis due to ESRD and suffering from heart failure with reduced ejection fraction. Because of worsening heart failure and hypertension, she was prescribed with sacubitril/valsartan at a dose of 50 mg twice a day, spironolactone at a dose of 20 mg three times a day and metoprolol at a dose of 23.75 mg once daily. There was a symptomatic improvement with the heart failure and reduction in NT-proBNP level, accompanied by a decrease of blood pressure after using sacubitric/valsartan. In conclusion, it is safe and effective to take sacubitril/valsartan in this hemodialysis patient with severe heart failure.

关 键 词：End Stage Renal Disease Sacubitril/Valsartan HEMODIALYSIS Heart Failure Reduced Ejection Fraction 

分 类 号：R69[医药卫生—泌尿科学]